Combination of anti-proliferative signalling activation for the treatment of pituitary tumors
Current therapies for pituitary adenomas focus on stimulating somatostatin receptors (SSTRs) that inhibit cell proliferation and hormone secretion. However, half of patients become resistant to the SST analogue Octreotide (OCT), with the search for alternative strategies that overcome such resistanc...
Guardado en:
| Autores principales: | Picech, F, Sosa, L, Mukdsi, J, Torres, A, Petiti, J |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2019
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/26190 |
| Aporte de: |
Ejemplares similares
-
Trastuzumab inhibits pituitary tumor cell growth modulating the TGFB/SMAD2/3 pathway
por: Petiti, Juan Pablo, et al.
Publicado: (2023) -
Update on mechanisms of pituitary tumorigenesis
por: Cecenarro, Laura Anahi, et al.
Publicado: (2021) -
EZH2 as a regulator of cell proliferation in pituitary tumors
por: Zlocowski , N, et al.
Publicado: (2021) -
Expresión de componentes del fenotipo secretor asociado a senescencia en un modelo murino de tumor pituitario neuroendócrino
por: Ramírez, JY, et al.
Publicado: (2024) -
VEGF and CD31 association in pituitary adenomas
por: Cristina, C., et al.